Genmab A/S (GMAB)
After hours:
| Previous close | 31.93 |
| Open | 31.86 |
| Bid | 32.09 x 800 |
| Ask | 32.40 x 900 |
| Day's range | 31.86 - 32.56 |
| 52-week range | 26.19 - 47.28 |
| Volume | |
| Avg. volume | 606,355 |
| Market cap | 20.853B |
| Beta (5Y monthly) | 0.62 |
| PE ratio (TTM) | 42.28 |
| EPS (TTM) | 0.76 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 41.53 |
- GlobeNewswire
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement COPENHAGEN, Denmark; September 27, 2022 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 18,406 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 133 shares at DKK 815.50,3,874 shares at DKK 939.50,367 shares at DKK 962.00,8,949 shares at DKK 1,025.00,878
- GlobeNewswire
Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK® (tisotumab vedotin-tftv)
-- Zai Lab Obtains Exclusive Rights to Develop and Commercialize TIVDAK, an FDA-approved First-in-Class Antibody-Drug Conjugate (ADC), in Mainland China, Hong Kong, Macau, and Taiwan -- -- Zai Lab will Leverage its Leadership in Women’s Cancer in China to Commercialize and Expand Patient Access to TIVDAK -- -- Collaboration Supports Regional Patient Enrollment for InnovaTV 301, a Global Phase 3 Trial of TIVDAK in Patients with Recurrent or Metastatic Cervical Cancer -- SHANGHAI and CAMBRIDGE, Ma
- GlobeNewswire
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Company Announcement COPENHAGEN, Denmark; September 20, 2022 – Genmab A/S (Nasdaq: GMAB) announced today that the board decided to grant 19,782 restricted stock units and 19,789 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a right and obligation to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the date of gr
